151 related articles for article (PubMed ID: 38789848)
1. A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [
Hanley MJ; Zhang S; Griffin R; Zhu SX; Fram RJ; Lin J; Venkatakrishnan K; Gupta N
Invest New Drugs; 2024 May; ():. PubMed ID: 38789848
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer.
Gupta N; Pierrillas PB; Hanley MJ; Zhang S; Diderichsen PM
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):731-744. PubMed ID: 35316867
[TBL] [Abstract][Full Text] [Related]
3. Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products.
Zhang S; Jin S; Griffin C; Feng Z; Lin J; Baratta M; Brake R; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1028-1043. PubMed ID: 34118178
[TBL] [Abstract][Full Text] [Related]
4. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
[TBL] [Abstract][Full Text] [Related]
5. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
6. Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.
Gupta N; Largajolli A; Witjes H; Diderichsen PM; Zhang S; Hanley MJ; Lin J; Mehta M
Clin Pharmacol Ther; 2022 Aug; 112(2):327-334. PubMed ID: 35467009
[TBL] [Abstract][Full Text] [Related]
7. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for
Yang JC; Zhou C; Jänne PA; Ramalingam SS; Kim TM; Riely GJ; Spira AI; Piotrowska Z; Mekhail T; Garcia Campelo MR; Felip E; Bazhenova L; Jin S; Kaur M; Diderichsen PM; Gupta N; Bunn V; Lin J; N Churchill E; Mehta M; Nguyen D
Expert Rev Anticancer Ther; 2023 Jan; 23(1):95-106. PubMed ID: 36537204
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
[TBL] [Abstract][Full Text] [Related]
9. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
Russell MC; Garelli AM; Reeves DJ
Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
[TBL] [Abstract][Full Text] [Related]
10. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial.
Zhou C; Ramalingam SS; Kim TM; Kim SW; Yang JC; Riely GJ; Mekhail T; Nguyen D; Garcia Campelo MR; Felip E; Vincent S; Jin S; Griffin C; Bunn V; Lin J; Lin HM; Mehta M; Jänne PA
JAMA Oncol; 2021 Dec; 7(12):e214761. PubMed ID: 34647988
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Christopoulos P; Prawitz T; Hong JL; Lin HM; Hernandez L; Jin S; Tan M; Proskorovsky I; Lin J; Zhang P; Patel JD; Ou SI; Thomas M; Stenzinger A
Lung Cancer; 2023 May; 179():107191. PubMed ID: 37058788
[TBL] [Abstract][Full Text] [Related]
12. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Zhang W; Dong X
J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
[TBL] [Abstract][Full Text] [Related]
13. Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Huang WS; Li F; Gong Y; Zhang Y; Youngsaye W; Xu Y; Zhu X; Greenfield MT; Kohlmann A; Taslimi PM; Toms A; Zech SG; Zhou T; Das B; Jang HG; Tugnait M; Ye YE; Gonzalvez F; Baker TE; Nadworny S; Ning Y; Wardwell SD; Zhang S; Gould AE; Hu Y; Lane W; Skene RJ; Zou H; Clackson T; Narasimhan NI; Rivera VM; Dalgarno DC; Shakespeare WC
Bioorg Med Chem Lett; 2023 Jan; 80():129084. PubMed ID: 36423823
[TBL] [Abstract][Full Text] [Related]
14. Mobocertinib: Mechanism of action, clinical, and translational science.
Hanley MJ; Camidge DR; Fram RJ; Gupta N
Clin Transl Sci; 2024 Mar; 17(3):e13766. PubMed ID: 38511563
[TBL] [Abstract][Full Text] [Related]
15. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with
Riely GJ; Neal JW; Camidge DR; Spira AI; Piotrowska Z; Costa DB; Tsao AS; Patel JD; Gadgeel SM; Bazhenova L; Zhu VW; West HL; Mekhail T; Gentzler RD; Nguyen D; Vincent S; Zhang S; Lin J; Bunn V; Jin S; Li S; Jänne PA
Cancer Discov; 2021 Jul; 11(7):1688-1699. PubMed ID: 33632775
[TBL] [Abstract][Full Text] [Related]
16. Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations.
Wang J; Lam D; Yang J; Hu L
Med Chem Res; 2022; 31(10):1647-1662. PubMed ID: 36065226
[TBL] [Abstract][Full Text] [Related]
17. Severe Psychiatric Symptoms in a Patient With
Kamel J; Meeder N; Cuellar S; Chan D; Huber M; Pasquinelli M; Hulbert A; Khaddour K; Feldman L
JTO Clin Res Rep; 2021 Nov; 2(11):100241. PubMed ID: 34766066
[TBL] [Abstract][Full Text] [Related]
18. Targeting
Han H; Li S; Chen T; Fitzgerald M; Liu S; Peng C; Tang KH; Cao S; Chouitar J; Wu J; Peng D; Deng J; Gao Z; Baker TE; Li F; Zhang H; Pan Y; Ding H; Hu H; Pyon V; Thakurdin C; Papadopoulos E; Tang S; Gonzalvez F; Chen H; Rivera VM; Brake R; Vincent S; Wong KK
Cancer Res; 2021 Oct; 81(20):5311-5324. PubMed ID: 34380634
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of Mobocertinib in the Treatment of NSCLC - Patient Selection and Reported Outcomes.
Arnold A; Ganti AK
Onco Targets Ther; 2023; 16():559-569. PubMed ID: 37456145
[TBL] [Abstract][Full Text] [Related]
20. Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations.
Vasconcelos PENS; Kobayashi IS; Kobayashi SS; Costa DB
JTO Clin Res Rep; 2021 Mar; 2(3):. PubMed ID: 33728415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
